Geographic accessibility and risk of hospitalization and mortality among patients with chronic respiratory diseases by Ghaderi, Gelareh
  
GEOGRAPHIC ACCESSIBILITY AND RISK OF 
HOSPITALIZATION AND MORTALITY AMONG PATIENTS 
WITH CHRONIC RESPIRATORY DISEASES 
 
 
 
by © Gelareh Ghaderi 
A thesis submitted to the School of Graduate Studies in partial fulfillment of 
the requirements for the degree of 
 
Master of Science in Medicine (Clinical Epidemiology) 
Discipline of Clinical Epidemiology, Faculty of Medicine 
Memorial University of Newfoundland 
 
 
 
 
 
October 2019 
St. Johns   Newfoundland and Labrador 
ii 
 
Abstract 
Spatial differences exist in hospitalization and mortality among patients with Chronic 
Obstructive Pulmonary Disease (COPD) and asthma. Objective: Examine the 
association between geographic accessibility, hospitalization, and mortality among 
COPD and asthma patients in Newfoundland and Labrador (NL). Methods: A 
retrospective cohort of adults diagnosed with COPD and asthma were followed from 
diagnosis until hospitalization, death or end of the study. Geographic accessibility was 
defined using accessibility-remoteness index. Multivariate and geospatial analyses 
were performed. Result: We identified 44876 (43.8% inaccessible) COPD patients and 
28316 asthma patients (37.4% inaccessible). Living in inaccessible areas increased 
hospitalization incidence for COPD (OR=2.57, 95% CI 1.54-4.25, P<0.00136) and 
asthma (OR=12.38, 95% CI:6.28-24.46, P<0.001). Mortality was associated with 
geographic accessibility only for COPD (OR=10.73, 95% CI; 2.27-44.77, P=0.002). 
COPD hospitalization (MI=0.034, p<0.03), mortality (MI=0.047, p<0.011) and asthma 
hospitalization (MI=0.065, p<0.001) were spatially autocorrelated. Conclusion: Living 
with chronic respiratory diseases in NL’ remote areas increases risk of hospitalization. 
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Chapter 1: Introduction and Overview 
1.1. Problem Statement 
Hundreds of millions of people deal with chronic respiratory diseases. 
According to the World Health Organization (WHO), chronic respiratory diseases are 
diseases affecting airways and other structures of lungs [1]. Chronic Obstructive 
Pulmonary Disorder (COPD) and asthma are two of the most prevalent of their kind, 
even though these two diseases are preventable and manageable [2]. 
The prevalence of COPD and asthma are increasing in most regions of the world 
[3][4]. With the aging population, the number of patients who are affected by these 
conditions, and subsequently, the number of deaths will increase [5]. Moreover, most 
of the patients living with chronic respiratory diseases have poor access to healthcare 
services [6]. 
COPD is one of the major reasons of mortality and morbidity. In the United 
States, COPD is recognized as one of the most expensive chronic diseases, the majority 
of it is due to hospitalizations. Both medical costs and indirect medical costs of asthma 
are considerable [7]. According to literature, the main direct costs are due to 
hospitalization and medication of asthma patients [8]. The Annual deaths of asthma are 
estimated to be about 250000 in the world. These rates vary in the different parts of the 
world [7].  
Although the mortality and hospitalization of COPD and asthma are high, they 
are preventable. With proper management, and treatment, exacerbation of these 
diseases can be prevented, and consequently hospitalization and mortality will 
decrease.  
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Inequity exists in hospitalization and mortality of patients living with COPD 
and asthma. One of the main factors which contributes to this inequity is the geographic 
differences. The literature on the geographical differences of asthma and COPD 
hospitalization and mortality is limited. Outside of a small number of non-generalizable 
research projects. Previous studies have failed to address the impacts of geographic 
accessibility on hospitalization and mortality among chronic respiratory disease 
patients. 
To our knowledge, this is the first study in Newfoundland and Labrador (NL) 
which examines the effect of geographic accessibility on hospitalization and mortality 
among chronic respiratory disease patients. The results of this study will help policy 
makers recognize the current situation of asthma and COPD hospitalization in the 
province, it will also assist in the provision of healthcare regarding these issues in NL. 
In this thesis, we begin by explaining the concepts of COPD, asthma, geography 
differences, and the objectives of the study. In the second chapter, we focus on COPD 
hospitalization and mortality. In the third chapter, the effect of geographic accessibility 
of asthma hospitalization and mortality will be investigated.  The final chapter presents 
a summary of the results and conclusion. 
1.1.  What is COPD? 
COPD is a disease in which airflow obstruction is present due to emphysema, 
chronic bronchitis or small airway diseases. This airway obstruction gradually 
progresses; however, it can be partially reversible, and it can coexist with airway 
hyperreactivity [9]. Emphysema is described when the lung alveoli are enlarged or 
destroyed, and Chronic bronchitis is characterized for a chronic condition by phlegm 
and chronic coughing, and small airway diseases which refer to a condition with 
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narrowed small bronchioles. Airflow obstruction is usually determined using a 
spirometry test. During the spirometry test, the volume of air exhaled within the first 
second (Forced Expiratory Volume [FEV1]) and total volume of air exhaled (Forced 
Vital Capacity [FVC]) will be measured. Patients with airflow obstruction, associated 
with COPD have lower FEV1/FVC ratio [10]. 
Three hundred twenty-eight million people of which 168 million are men, and 
160 million are women, are affected by COPD in both developing and developed 
countries [6]. This disease is the fifth leading cause of death in the world [11].  It is 
predicted that it will be the third leading cause of death by the year 2020 [12]. In 
Newfoundland and Labrador, COPD makes up 3.4 percent of hospital admission. 
According to Statistics Canada, in 2014, 4.9% (15,280 people) of NL population were 
living with COPD. [25]. 
1.2.  COPD Exacerbation and Hospitalization 
COPD exacerbation is defined as an event that is characterized by a change in 
the patient’s baseline symptoms such as dyspnea, cough or sputum. Exacerbation is 
different from daily variations and may require a medication different from the patient’s 
routine medication [13]. COPD exacerbation contributes to the progression of the 
disease [10]. Age, severity of emphysema, history of asthma, and systemic 
inflammation are risk factors of hospital admission due to exacerbation for COPD 
patients [14]. COPD exacerbation can be triggered by other risk factors including heart 
failure, pollution, allergen, sedative. Among them, respiratory infection is known as the 
main factor of COPD exacerbation [15].  
COPD hospitalization is caused by exacerbation, and respiratory failure. 
Previous clinical population studies of COPD patients indicate that COPD exacerbation 
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commonly lead to hospitalizations. This increases the likelihood of hospital 
readmission and mortality.  
1.3.  Geographic Differences of COPD Hospitalization and Mortality 
A very few studies have investigated the geographic variation in hospitalization 
of COPD patients. These studies mostly investigate rural-urban differences that exist in 
spatial disparity of COPD. 
One study in Victoria, Australia assessed the geographic variation of COPD 
admission rates between rural and urban areas. The purpose of the study was to identify 
areas which require public health intervention to improve access to healthcare services. 
The results indicate that admission rates were higher in rural Victoria when compared 
to urban Victoria (rate ratio of 1.29, 95% CI: 1.11-1.51). A significant association was 
seen between the remoteness of area and hospitalization rates [16]. 
In another investigation from New Zealand the distribution of hospitalization 
regarding age, socio-economic status, length of stay, and ethnicity were studied over a 
5-year period. The results showed a higher admission rate in rural areas. Their result 
indicates the need for intervention to provide equal public health services for COPD 
patients [17].  
Another study in the United States assessed whether COPD related mortality is 
higher in rural and remote areas. This study was a retrospective cohort, conducted in 
129 acute Care Veteran Affairs hospitals. The primary outcome of this study was 
mortality 30 days after admission. The results indicate higher mortality in patients who 
live in remote and rural areas in comparison to urban areas (5% vs. 3.8, p=0.002). 
Patients who live in isolated rural areas are prone to exacerbation and mortality. The 
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results helped policy makers identify the needs of different regions and attempt to 
narrow the gaps [18].  
1.4.  What is Asthma? 
Asthma is “a chronic inflammatory disorder of the airways in which many cells 
play a role, including mast cells and eosinophils. In susceptible individuals, this 
inflammation causes symptoms that are usually associated with widespread but variable 
airflow obstruction that is often reversible, either spontaneously or with treatment, and 
causes an associated increase in airway responsiveness to a variety of stimuli” [19]. 
Unlike COPD, asthma affects both adults and children. Approximately 300 million 
people suffer from asthma worldwide [20]. In Canada, 13% of the population deals with 
asthma.  
1.5. Asthma Exacerbation and Hospitalization 
Expert Panel Report 3 (EPR-3) defines asthma exacerbation as “acute or 
subacute episodes of progressively worsening shortness of breath, cough, wheezing, 
and chest tightness—or some combination of these symptoms” [21]. In clinical trials 
acute exacerbation of asthma is defined as “the need for treatment with systemic 
corticosteroids, hospital admission or emergency treatment for worsening asthma, or a 
decrease in morning peak flow >25% baseline on two consecutive days” [20]. The main 
cause of asthma exacerbation is respiratory infection due to rhinoviruses. Asthma 
patients that have a history of hospitalization from exacerbation are in a higher risk of 
future exacerbation. Previous research shows that hospital admission due to asthma 
exacerbation is related to the severity of the disease. The study shows from asthma 
patients with 3 or more exacerbations per years, 5% was considered as mild, 13% 
moderate, and 54% as severe [22]. The risk of recurrent exacerbations is higher among 
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women, obese individuals, patients with obstructive sleep apnoea, chronic sinusitis, 
gastroesophageal reflux, or respiratory infections [23]. 
Death as a result of asthma exacerbation is not common. It is highly preventable 
and mainly due to poor healthcare services. There is a higher risk of mortality due to 
asthma exacerbation for: women, obese individuals, elderly, smokers, asthma patients 
noncompliant with medications, and a previous near-fatal attack [23]. 
1.6.  Geographic Differences of Asthma Hospitalization and Mortality 
Geographic variation exists in asthma hospitalization and mortality. One study 
identified disparity in different neighbourhoods of New York city. This study suggests 
access to healthcare facilities, health literacy, and community status have significant 
impacts on these differences.  
Another study in Canada analyzed rural-urban differences of asthma 
hospitalizations in Saskatchewan between 1970 and 1989. The authors suggest that 
higher hospital admission rates in rural areas of Saskatchewan may be due to grain 
farming which is the main occupation in those areas. In addition, rural residents with 
mild asthma are more likely to get hospitalized, as the greater distance to hospitals 
makes it difficult to return home before complete treatment [24].  
As previous research indicates geographical inequality exists in COPD and 
asthma hospitalization and mortality. This could be due to the existence of inequity in 
access to health care services geographically. In rural areas, it is expected that access 
to the health services will be lower, which partially can justify the findings of the 
previous researches.  
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1.7.  Thesis Objective 
The overall objective of this study is to identify the spatial disparity that exists 
in hospitalization, and mortality of the patients with chronic respiratory diseases (i.e. 
COPD, and Asthma) in Newfoundland and Labrador. More specifically we aim to 
assess: 
1) Effects of the place of residence on hospitalization of COPD patients older 
than 35 years old 
2) Effects of the place of residence on mortality of COPD patients older than 
35 years old 
3) Effects of the place of residence on hospitalization of asthma patients older 
than 20 years old 
4) Effect of the place of residence on mortality of asthma patients older than 
20 years old 
1.8.  Research Questions 
1) In adults older than 35 (by gender, by age) diagnosed with COPD in 
Newfoundland and Labrador between 1995 and 2014, does accessibility of 
the place of residence affect hospitalization? 
2) In adults older than 35 (by gender, by age) diagnosed with COPD in 
Newfoundland and Labrador between 1995 and 2014, does accessibility of 
the place of residence affect mortality? 
3) In adults older than 20 (by gender, by age) diagnosed with asthma in 
Newfoundland and Labrador between 1995 and 2014, does accessibility of 
the place of residence affect hospitalization? 
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4) In adults older than 20 (by gender, by age) diagnosed with asthma in 
Newfoundland and Labrador between 1995 and 2014, does accessibility of 
the place of residence affect mortality? 
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Chapter 2: Geographic Accessibility and Risk of Hospitalization and 
Mortality among COPD Patients 
 
2.1. Introduction 
Chronic Obstructive Pulmonary Disease (COPD) is the fifth leading global 
cause of morbidity [1], and it is predicted that it will be the third leading cause of death 
by the year 2020 [2]. COPD has a significant impact on healthcare costs, primarily due 
to acute exacerbations requiring hospital admission [3]. Preventing COPD 
hospitalization is a focus in COPD management as the risk of readmission and mortality 
is higher in patients hospitalized for COPD exacerbation [3]. Even though COPD is 
recognized as an Ambulatory Care-Sensitive Condition (ACSC) and hospital 
admissions are avoidable through proper use of primary health care services and early 
management. COPD is still the primary cause of admission and readmission to hospitals 
among the ambulatory Care Sensitive Conditions (ACSC) [4][5]. 
Identifying the factors that influence hospitalization is essential to COPD 
management and has significant healthcare implications [3]. Previous studies suggest 
that the health outcomes of patients living with COPD are worse in rural and remote 
areas [6]. More recent evidence suggests that as the rurality of a patient’s residence 
increases the rate of COPD hospitalization also increases, this could indicate the 
inequity of primary healthcare in rural areas [7]. 
There is little information available to conclude that the level of geographic 
accessibility to healthcare facilities is a predictor of hospitalization rate for COPD 
patients. A study in Australia argues that a strong predictor of COPD hospitalization is 
the degree of remoteness of patient’s place of residence  [7]. The study also showed 
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COPD admission rates were higher in rural areas (rate ratio of 1.29, 95% CI: 1.11-1.51) 
of Australia [7]. A retrospective cohort study in the United States found higher COPD 
mortality rates in rural and remote areas (5% vs. 3.8%, P<0.002) [6]. They concluded 
patients who live in isolated rural areas are prone to exacerbation and mortality [6]. The 
previous studies are limited to their geography, and their results are not generalizable. 
For instance, country specific uniqueness was observed when comparing the results of 
studies which looked to determine the level of rural-urban differences in health status 
and mortality between Canada and Australia [8].  
A cross sectional study using the Canadian Community Health Survey’s 
(CCHS) data from the 10 Canadian provinces found inequity in access to healthcare 
services between rural and urban areas [9]. In Newfoundland and Labrador (NL),  
COPD makes up 3.4 percent of all hospital admissions in 2013-2014 [10]. In order to 
reduce and prevent COPD hospitalizations and mortality, effective health policies 
should be implemented. This requires a better understanding of the distribution of those 
living with COPD and identifying areas that could benefit the most from increased 
resource allocation or a change in the provision of healthcare services. To our 
knowledge this is the first study in NL investigating the association between patient’s 
place of residence and COPD hospitalization and mortality among adults. This study 
aims to determine whether the risk of hospitalization and mortality is higher among 
COPD patients who live in inaccessible areas. Our study hypothesis is that COPD 
hospitalization and mortality is higher among patients who live in areas with lower 
geographic accessibility to healthcare services.  
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2.2.  Methods 
This study uses a retrospective cohort design which considers all adults older 
than 35 years in NL. It includes all patients who are diagnosed after 1995 in the 
province. Patients are followed from the date of diagnosis until the occurrence of the 
outcome, their death or the end of the study period (2014) whichever came first.  
2.2.1. Data Sources 
We used a population-based dataset which includes all individuals who received 
any healthcare services between 1995 to 2014 in Newfoundland and Labrador, 
containing more than 600,000 records. The dataset was provided by Newfoundland and 
Labrador Centre for Health Information (NLCHI) and developed by linking the 
following databases: 
1) the Canadian Chronic Surveillance System (CCDSS) database, which is a 
collaborative network of surveillance systems of provinces supported by the Public 
Health Agency of Canada [11]. 
2) Clinical Database Management System (CDMS) database which is related to 
in-patients services and surgical day care services from acute care facilities [12]. 
 3) Medical Care Plan (MCP) Fee-For-Service Physician Claims Database [13]. 
4) NLCHI Mortality System (MS) providing information about all the deaths 
within the province [14].  
The dataset includes information about patient characteristics, number of 
physician and specialist visits, number of hospitalizations, and number of comorbidities 
according to validated CCDSS case definitions for chronic diseases using the 
International Classification of Diseases and related health problems (ICD) 9th and 10th 
revision [7].  
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2.2.2. Ethics and Consent 
This study was granted ethics approval with reference number 20161500 from 
the Health Research Ethics Board in Newfoundland and Labrador.  
2.2.3. COPD Case Definition 
We used the CCDSS case definition of COPD to select patients for our analysis 
[15]. Our COPD case definition considered individuals 35 years or older, who are 
registered under the NL provincial health insurance plan. To be considered as a COPD 
case, individual should either have had a hospitalization visit that resulted in a COPD 
diagnosis based on ICD-9, or ICD-10 codes (491; 492; 496 in ICD-9, J41; J42; J43; J44 
in ICD-10), or a physician visit with a COPD diagnosis (491; 492; 496 in ICD-9). This 
case-definition algorithm has been validated for the provinces of Ontario with a 
sensitivity of 85%, and specificity of 78% [16].  
2.2.4. Geographic Accessibility 
Our main exposure is living in remote and inaccessible areas. Accessibility 
refers to the road distance between the place of residence and the specific public 
services. We used Accessibility-Remoteness (A-R) index in order to geographically 
classify areas across the province and to create categorical classes which ranged from 
highly accessible to extremely remote. The A-R index was developed by the 
Newfoundland and Labrador Statistics Agency (NLSA) as a tool to classify the 
province’s communities. The index categorizes the areas based on accessibility to 
government and community services including primary and secondary health centres, 
pharmacies, dental clinics, high schools, and supermarkets. The index is a geographical 
approach defining accessibility based on distances between region or community 
centroids and community services. It concentrates on the fact that distance hinders the 
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interaction between people and these services. In general, areas with the highest 
accessibility are regional centres with high numbers of governmental services in close 
proximity, such as health centres, while communities with the lowest accessibility are 
characterized as being extremely remote, requiring the use of a ferry or plane to reach 
regional centres [17].  
 
Figure 2.1. Classification of the province of Newfoundland and Labrador based on A-R  
 
Our analysis used the NLSA A-R index as the underlying framework to 
determine the range of accessibility which attributes to both rural and urban classes. As 
illustrated in figure 2.1, the index categorizes regions of the province across the 
following six categories: highly accessible, accessible, somewhat accessible, 
moderately remote, and extremely remote areas. We categorized all six categories into 
two previously defined classes: accessible and inaccessible.  For individual level 
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analysis, we used the continuous A-R index scores which were assigned to each patient 
by spatially joining their postal codes to the regions depicted in figure 2.1. Community 
level analysis considered discrete classes developed through fuzzy set model. Fuzzy set 
model enabled us to assign varying degrees of membership for accessibility based on 
A-R index scores. Somewhat accessible (remote index value = 0.329) was identified as 
an appropriate cut off point for remoteness. The index score of 0.329 was used as a cut-
off point where all index scores were divided by this number. Any values close to that 
index score approaching a value of 1 was considered as a part of the “accessible” 
community class.  This allowed for the assignment of membership for index scores that 
fell into A-R index classes below “somewhat accessible”. After creating the histogram 
of the transformed fuzzy index scores, we concluded that the 50th percentile would be 
a good cut-off to assign membership across “accessible” and “inaccessible” classes 
where anything above would be deemed “accessible” and anything below is 
“inaccessible” [18].  We used these two subsets of the results of the fuzzy model for 
the descriptive and community level analysis. 
2.2.5. Outcome 
The primary outcome of this study is hospitalization. Hospitalization is a 
dichotomous (yes or no) variable, and it is an incidence case which describes if the 
person had any hospitalization record, planned or unplanned, during the observation 
period. We measured hospitalization as any hospitalization per person-year at risk. 
The second outcome is annual hospitalization rate, it is a numerical variable 
indicating the number of hospitalizations for each patient per year during the follow up 
period and measured per person-year at risk. The third outcome is mortality, another 
binary variable that indicates whether the person is alive during the study period.  
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2.2.6. Covariates  
The variables at the patient level were collected and derived from the list of 
variables consisting of: sex, age at the time of diagnosis, number of comorbidities 
before their first hospitalization, total number of comorbidities recorded during the 
study period, and number of physician and specialist visits during the study period.  
Patient comorbidities were identified using CCDSS algorithms and ICD-9/ICD-
10 codes including diabetes, hypertension, asthma, ischemic heart disease (IHD), acute 
myocardial infarction (AMI), and heart failure. For the purposes of descriptive analysis 
and the development of regression models, patients were categorized based on the 
number of comorbidities (0, 1, 2, ≥3). Individuals were placed into 10-year age groups 
based on the time they were diagnosed [19]. 
For analysing where the dependent variable was hospitalization, total number 
of visits with family physicians, pulmonologists, internists, and other specialists from 
the date of diagnosis to the first admission to hospital, and total number of comorbidities 
before the first a patient’s first hospitalization were considered. For analyses of 
hospitalization rate and mortality, the following exploratory variable were used: total 
number of visits with family physicians and specialists during the follow-up period, and 
total number of comorbidities.  
2.2.7. Analysis 
2.2.7.1. Individual Level Analysis 
Descriptive analysis was performed to describe the characteristics of the study 
population at baseline. Bivariate analyses were performed to assess the differences 
between inaccessible and accessible areas. 
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We assessed the association between COPD hospitalization, and place of 
residence (inaccessible versus accessible) using binomial regression. The outcome 
variable is hospitalization (yes or no), and the main exposure variable is geographic 
accessibility, measured by A-R index. The result was adjusted for the number of 
comorbidities, gender, age, and physician and specialist visits. A stepwise approach 
was used to select variables that produced the best fit model (smaller Akaike 
information criterion (AIC)). The model with the variables, “visit with specialists” and 
“visits with family physicians” was found to have a better fit compared to the model 
including “visits with pulmonologists”, “visits with internists”, and “visits with other 
specialists” separately. Therefore, for this study we used the variables “visit with family 
physicians” and “visit with specialists” as co-varieties in the model. To account for the 
difference in duration for each patient’s follow-up period, the model was fitted with a 
generalized linear model with “Complementary log-log function” and an offset term as 
log of follow-up (person-year at risk) [20], [21], [22], [23]. Person-year (PY) was 
calculated for each patient, and it was defined as the number of years from COPD 
diagnosis until first admission to hospital (if hospitalized), death or end of the study (if 
not hospitalized). A similar approach was used where we assessed the association 
between geographic accessibility and mortality. 
The association between geographic accessibility and hospitalization rate was 
assessed by developing a regression model. Performing the Poisson model, the ratio of 
residual deviance and residual degree of freedom was greater than one, and over 
dispersion was suspected. Using overdispersion test by Cameron and Trivedi [24] 
indicated overdispersion exists in the data selected for analysis (P<0.05), therefore the 
model was fitted using negative binomial instead of Poisson regression. 
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The log of follow-up was added as an offset term to the model to control for 
differences in follow-up periods present in patient records. The result was adjusted for 
the number of comorbidities, gender, age, general physician visits, and specialist visits. 
In the analysis, an alpha of 0.05 was considered as the cut off point for specifying 
statistical significance. All statistical analyses were conducted using R studio 
Version 1.1.383 [25]. 
2.2.7.2. Spatial Analysis 
The distribution of hospitalization, annual hospitalization rate, and mortality are 
visualized at the local areas level. Local areas are based on Census Consolidated 
subdivision (CCS) which is a spatial level between census division and census 
subdivision [26]. To find out if any clusters exist in the spatial distribution of outcomes, 
a geospatial analysis was conducted using shapefiles provided by the NLSA. To 
identify spatial clusters, a spatial autocorrelation tool (Global Moran’s I and Anselin 
Local Moran’s I) was applied to summarize and geolocate data.  If spatial 
autocorrelation was detected, either globally and/or locally, an ordinary least squares 
regression was used to find the best model that predicts COPD hospitalization and 
mortality at the community level. Anselin Local Moran’s I helps to find clusters and 
outliers. Cluster refers to when a feature has neighbors with a similar high or low value. 
That feature is a part of the cluster, and the level of significant is at 95% confidence 
interval. On the other hand, outlier refers to when a feature had neighbours with 
dissimilar value. For instance, the feature’s value is high, while its neighbors’ values 
are low, this is called high-low outlier.  
 Regression residuals were mapped and tested for autocorrelation which 
indicates whether spatial dependencies exist. The predictor variables were selected 
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from the following variables: average A-R index score, percentage of female population 
with COPD, average age at time of diagnosis, percentage of COPD patients with 
comorbidities, average number of family physician visits, and specialist visits during 
the follow-up period at the community level. Using a stepwise approach, the 
explanatory predictors (p-value<0.1) were selected and the best-fitted model was 
developed. 
2.3. Results 
There were 52,158 patients who were identified as being diagnosed with COPD 
based on our case definition. As the place of residence was the focus of this study, 
patients with missing residential postal codes (14% of all records) were removed. A 
total population of 44,876 COPD patients with 44.05% in inaccessible areas (n=19,768) 
were enrolled in the study and were followed from 1995 and to 2014. Figure 2.2 shows 
the distribution of the cumulative incidence of COPD. As seen, some areas in east and 
west of Newfoundland have higher cumulative incidence including Trepassey Bay 
(0.74), Head of Conception Bay (0.42), Bonne Bay area (0.38), Bay of Islands (0.38), 
and St. Mary’s Bay (0.34). The results of descriptive analysis were presented in tables 
2.1 and 2.2.  41.1% of COPD patients died during the study period. Mortality of COPD 
patients was 5.1 per 100 person-year. The total person-years at risk was 358,683 PYs. 
On average, COPD patients were followed 7.993 (95% CI: 7.94-8.04) years. There were 
approximately 3.783 (95% CI: 3.74-3.83) years between COPD diagnosis and first 
hospitalization. The mean age at the time of diagnosis was 63.03 [95% CI: 62.90-
63.17]. The youngest COPD patient at the time of diagnosis was 35 and the oldest 
COPD patient at the time of diagnosis was 104. The proportion of COPD patients 
increased with age: the highest proportion among the 60-69 age group. Patients with no 
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comorbidities before the first hospitalization and the whole of the study period are lower 
in accessible areas, 22.6% versus 24.8% and 17.8% versus 18.9%. The most common 
comorbidity was hypertension (65.6%) followed by ischemic heart disease (35.4%).  
The results included in Table 2.3 using person-years at risk indicates that 
healthcare utilization is significantly impacted by the accessibility of a patient’s place 
of residence. The hospitalization incidence among COPD patients who live in 
accessible areas (0.19 per PY) was higher than those in inaccessible areas (0.15 per PY) 
of the province (p<0.001). Thirty-nine-point four percent of COPD patients in 
inaccessible areas were readmitted within 30 days, whereas 31.5% of the patients from 
accessible areas were readmitted in this time period.  The annual hospitalization rate 
for COPD patients in inaccessible areas (0.47 per PY) was significantly higher than 
accessible areas, 0.35 per PY (p<0.001).  
Table 2.1. Mortality, total person-year at risk and fellow up period for patients diagnosed with 
COPD in NL 
Mortality per 100 Person-Year 5.1 
Total Person-Year at risk 358,683 
Average follow up (years) 7.993 (95% CI: 7.94-8.04) 
Average follow up before the first hospitalization 3.783 (95% CI: 3.74-3.83) 
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Figure 2.2. Distribution of cumulative incidence of COPD at the local area geographic 
level in NL 
 
Table 2.2. Characteristics of study population according to the place of residence (N=44876) 
 Inaccessible 
(n=19768) 
Accessible(n=25108) p-value a 
Sex (n, %)    
Male 10940 (55.3%) 12470 (50.7%) < 0.001 
Female 8828 (44.7%) 12368 (49.3%)  
    
Age in years b    
Median (IQR) 64 (53,75) 63 (51, 74) <0.001 
Mean (SD) 62.4 (14.4) 63.84 (15.2)  
Age group (n,%)    
<40 899 (4.5%) 1778 (7%) < 0.001 
40-49 2627 (13.3%) 3900 (15.5%)  
50-59 4039 (20.4%) 4982 (19.8%)  
60-69 4772 (24.1%) 5677 (22.6%)  
70-79 4630 (23.4%) 5313 (21.1%)  
>=80 2801 (14.3%) 3458 (14%)  
    
Comorbidities c (n, %)    
Zero  6880 (34.8%) 8476 (33.7%) 0.0147 
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Table 2.3. Health care utilization according to the place of residence 
 Inaccessible Accessible p-value 
Hospitalization incidence (PY) 0.19 0.15 <0.001 
    
Annual Hospitalization rate 0.47 0.35 <0.001 
 
Mortality 0.055 0.048 <0.001 
 
Visit with family medicine (rate)    
Before the first hospitalization (PY) 2.69 2.94 <0.001 
Total visits per year (PY) 8.11 9.85 <0.001 
    
Visit with Specialists (rate)    
Before the first hospitalization (PY) 2.07 2.30 0.004 
Total visits (PY) 6.44 7.61 <0.001 
    
Visit with Pulmonologists and 
internists (rate) 
   
Before the first hospitalization per 
(PY) 
0.55 0.57 0.26 
Total visits (PY) 1.55 1.73 0.002 
    
 
one 5940 (30%) 8083 (32.2%)  
Two 3554 (18%) 4593 (18.3%)  
Three or more 3394 (17.2%) 3956 (15.8%)  
    
Comorbidities d (n, %)   < 0.001 
Zero 4908 (24.8%) 5686 (22.6%)  
One 5996 (30.3%) 8183 (32.6%)  
Two 4409 (22.3%) 5872 (23.4%)  
Three or more 4455 (22.6%) 5367 (21.4%)  
    
Comorbidities e (n, %)   < 0.001 
Zero 3742 (18.9%) 4478 (17.8%)  
One 5094 (25.8%) 7127 (28.4%)  
Two 4432 (22.4%) 5705 (22.7%)  
Three or more 6500 (32.9%) 7798 (31.1 %)  
    
Mortality (n, %) 8373 (42.3%) 10063 (40%) < 0.001 
a Chi square test 
b Age at the time of diagnosis 
c Comorbidities at the time of diagnosis 
d Comorbidities before the first hospitalization 
e Comorbidities for the whole of the study period 
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2.3.1. Geographic Remoteness and Hospitalization 
2.3.1.1. Individual Level Analysis 
Table 2.4 shows findings from logistic regression model on the effect of 
geographic accessibility on hospitalization after adjustment for age, sex, number of 
comorbidities, number of family medicine, and specialist visits. Patients from areas 
with lower accessibility were more likely to be hospitalized than those from the areas 
with higher accessibility (OR=2.57, 95% CI 1.54-4.25, P value=0.00136). As the result 
of negative binomial model is illustrated in Table 2.5 the adjusted annual 
hospitalizations rate increases as accessibility decreases (RR=5.05, 95% CI:3.00-8.51, 
P value<0.001). 
Table 2.4. Effects of geographic accessibility on hospitalization among COPD patients 
Predictor OR 95% CI P-value 
AR INDEX a                 
Comorbidity b, c 
2.57 1.54-4.25 0.00136 
One             1.00 0.94-1.05 0.91 
Two             1.19 1.12-1.26 <0.001 
Three or more           2.12 2.00-2.25 <0.001 
Sex Female  0.85 0.83-0.87 <0.001 
Age 40-49 d, e 1.18 1.07-1.31 0.00242 
Age 50-59           1.81 1.65-1.99 <0.001 
Age 60-69 2.83 2.58-3.10 <0.001 
Age 70-79           4.72 4.30-5.18 <0.001 
Age >=80 5.47 4.97-6.03 <0.001 
AR INDEX: comorbidity=1   0.70 0.52-0.93 0.02352 
AR INDEX: comorbidity=2   0.71 0.51-0.97 004936 
AR INDEX: comorbidity>=3   0.37 0.27-0.52 <0.001 
AR INDEX: age 40-49 c      1.42 0.79-2.55 0.29658 
AR INDEX: age 50-59       1.13 0.65-1.99 0.69522 
AR INDEX: age 60-69      1.75 1.01-3.03 0.07545 
AR INDEX: age 70-79      1.91 1.10-3.34 0.04028 
AR INDEX: age >=80      2.79 1.57-4.97 0.00187 
a Accessibility Remoteness Index 
b Comorbidities before the first hospitalization 
c Patients with no comorbidities are the reference group. 
d Age 30-39 is used as the reference group. 
e Age at the time of diagnosis 
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Table 2.5. Effects of geographic accessibility on annual hospitalization rate among COPD 
patients 
Predictor RR 95% CI P-value 
AR INDEX a                 5.05 3.00-8.51 <0.001 
Comorbidity b    
One          1.11 1.05-1.18 <0.001 
Two             1.42 1.33-1.51 <0.001 
Three or more           2.21 2.08-2.35 <0.001 
Sex Female  0.87 0.83-0.90 <0.001 
Age 40-49 c, d 1.15 1.05-1.27 0.002 
Age 50-59           1.60 1.46-1.75 < 0.001 
Age 60-69 2.39 2.18-2.62 <0.001 
Age 70-79           3.55 3.24-3.88 < 0.001 
Age >=80 4.50 4.09-4.95 < 0.001 
Family Medicine visits e 1.0074 1.0072-1.0077 < 0.001 
Specialist visits f 0.9970 0.9969-0.9972 < 0.001 
AR INDEX: comorbidity=1   0.92 0.67-1.25 0.56 
AR INDEX: comorbidity=2   0.81 0.58-1.12 0.19 
AR INDEX: comorbidity>=3   0.70 0.52-0.95 0.019 
AR INDEX: Female 0.82 0.65-1.98 0.028 
AR INDEX: age 40-49 d       1.27 0.72-2.21 0.40 
AR INDEX: age 50-59       1.35 0.79-2.31 0.25 
AR INDEX: age 60-69      1.82 1.07-3.08 0.02 
AR INDEX: age 70-79      2.04 1.19-3.46 0.007 
AR INDEX: age >=80      2.34 1.34-4.10 0.002 
a Accessibility Remoteness Index 
b Number of comorbidities patients have until the end of study period 
c Age at the time of diagnosis 
d Age 30-39 is used as the reference group. 
e The family medicine visits for the whole study period. 
f The specialist visits for the whole study period. 
 
2.3.1.2. Spatial Analysis 
Cumulative incidence of hospitalizations among COPD patients by Local Area 
is presented in figure 2.3. Labrador North (0.98), Pinware River (0.96), Belle Bay 
(0.92), and Roddikton (0.91) were found to have the highest cumulative incidence of 
hospitalizations. The result of the global Moran’s I test points out a significantly small 
amount of (p-value <0.03) spatial autocorrelation at the significance level of 0.05. The 
Moran’s I index was 0.034 with a Z score of 2.21 (table 2.6), indicating overall positive 
27 
 
autocorrelation with a less than 1% chance that the clustered pattern observed was due 
to randomness. Anselin’s Local Moran’s I (LMI) identified local areas in the 
Grandfalls-Windsor region including Grandfalls-Point Leamington area (p-
value<0.014, LMI=0.00061) and other local areas in the Avalon Peninsula including 
Northeast Avalon (p-value<0.008, LMI=0.000221) as low-low clusters (figure 2.4). 
These areas have a lower cumulative incidence of hospitalizations as illustrated in 
figure 2.3 and relatively higher accessibility (figure 2.1). At the community level, a 
model which considered average age, average A-R index score, and percentage of total 
female in our study population produced the highest level of fitness (R2=0.52) in terms 
of the ability to predict the cumulative incidence of hospitalizations. The adjusted R2 
was 0.49, which shows the model explains approximately 49% of the variability in the 
dependent variable. The effect of A-R index was positive and significant (p<0.001). 
This indicates that at the community level, an increase in remoteness is significantly 
associated with an increase in the cumulative incidence of hospitalizations. The analysis 
of standard residuals did not show any spatial autocorrelation (Moran’s I= 0.026, p = 
0.1). The standard residuals of the over-prediction (>2.5 standard deviations) and 
under-prediction (<-2.5 standard deviation) at the local area level were not clustered. 
This provides evidence that while modelling at the community level, adjusting for 
spatial dependencies will not produce better model fitness in terms of predicting the 
cumulative incidence of hospitalizations of COPD patients.  
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Table 2.6. Results of Global Moran’s I test on cumulative incidence of hospitalization and annual 
hospitalization rate among COPD patients 
 Variable Cumulative incidence of hospitalizations 
Moran’s Index 0.034 
Z-score 2.21 
p-value 0.07 
 
Variable Annual hospitalization rate 
Moran’s Index 0.14 
Z-score 6.48 
p-value P<0.001 
 
 
Figure 2.3. Distribution of cumulative hospitalization incidence at local area level 1995-2014 
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Figure 2.4. Outlier and clusters of cumulative hospitalization incidence at local area level 1995-
2014 
 
Figure 2.5. Standard residuals of regression-adjusted hospitalization incidence at local area level 
Global Moran’s I =0.034 
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Results from the annual hospitalization rate analysis also indicated a clustered 
pattern with Moran’s I index score of 0.14 and a Z score of 6.48 (p-value <0.001). 
Anselin’s Local Moran’s I identified central and eastern Avalon Peninsula areas 
including Northeast Avalon (p-value<0.002, LMI=0.000288), and Grand Falls-Point 
Leamington Area (p-value<0.022, LMI=0.000041) as low-low clusters or cold spots. 
The northern peninsula of the island and the southern tip of Labrador which includes 
the Strait of Belle Isle (p-value<0.046, LMI=0.000086), Roddickton (p-value<0.04, 
LMI=0.000091), Hawks’ Bay-Port aux Choix (p-value<0.042, LMI=0.000016), 
Quirpon-Cook's Harbour (p-value<0.04, LMI=0.000057), and Pinware River (p-
value<0.026, LMI=0.000066) as high-high clusters or hot spots (figure 2.7). From 
figure 2.6 we observe that cold spot areas have the lowest annual hospitalization rates 
and are mostly accessible or moderately remote.  Hot spots were found in moderately 
remote to extremely remote areas. The results indicate not all the variability found in 
annual hospitalization rate across local areas can be justified by the A-R index alone. 
At the community level, the ordinary least squares regression model with the best fit 
(R2=0.60) included average age, average A-R index score, percentage of total female 
population, average number of comorbidities, and average number of family medicine 
visits. The model demonstrated that an increase in A-R index (decrease in accessibility), 
increase annual hospitalization rate at the local level (Coefficient=1.6, p-value <0.05). 
The residuals from this OLS model were depicted at the local area level (figure 2.8). At 
the global level, the standard residuals were also not found to be spatially autocorrelated 
(global Moran’s I = -0.003, p-value = 0.68) indicating a pattern that is not significantly 
different from random. 
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Figure 2.6. Distribution of annual hospitalization rate at area local level (1995-2014) 
  
 
Figure 2.7. Outlier and clusters of annual hospitalization rate at local area level 
 
Global Moran’s I =0.14 
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Figure 2.8. Standard residuals of regression – Adjusted annual hospitalization rate at local area 
level 
2.3.2. Geographic Remoteness and Mortality 
2.3.2.1. Individual Level Analysis 
   Table 2.7. represents the results of the regression model that was adjusted for 
patient comorbidities, sex, age, number of family medicine and specialist visits. 
Patients living with COPD in less accessible and remote areas were found to have a 
higher risk of death compared to those living in more accessible areas (OR=10.73, 95% 
CI; 2.27-44.77, P=0.002). 
 
Table 2.7. Effects of geographic accessibility on mortality among patients with COPD 
Predictor OR 95% CI P-value 
AR INDEX a                 11.25 2.34-47.97 0.002 
Comorbidity b, c                
One            0.93 0.85-1.01 0.11 
Two             1.16 1.06-1.27 0.002 
Three or more          1.79 1.65-1.95 < 0.001 
Sex Female  0.77 0.73-0.81 < 0.001 
Age 40-49 d, e 2.85 2.07-3.98 < 0.001 
33 
 
Age 50-59           7.97 5.90-10.94 < 0.001 
Age 60-69 20.48 15.23-27.96 < 0.001 
Age 70-79           46.78 34.81-63.84 < 0.001 
Age >=80 108.85 80.91-1.49 < 0.001 
Family Medicine visits f 0.9936 0.9933-0.9939 < 0.001 
Specialist visits g 1.0007 1.0005-1.0009 < 0.001 
AR INDEX: comorbidity=1   0.75 0.48-1.19 0.26 
AR INDEX: comorbidity=2   0.74 0.47-1.16 0.23 
AR INDEX: comorbidity>=3   0.65 0.43-00.99 0.06 
AR INDEX: Female 0.62 0.47-00.82 0.002 
AR INDEX: age 40-49 e       0.16 0.03-0.90 0.03 
AR INDEX: age 50-59       0.09 0.02-0.45 0.003 
AR INDEX: age 60-69      0.1 0.02-0.49 0.004 
AR INDEX: age 70-79      0.09 0.02-0.47  0.003 
AR INDEX: age >=80      0.11 0.02-0.53  0.005 
a Accessibility Remoteness Index 
b Number of comorbidities patients have until the end of study period 
c Patients with no comorbidities is the reference group. 
d Age at the time of diagnosis 
e Age 30-39 class is used as the reference group. 
f The family medicine visits for the whole study period. 
g The specialist visits for the whole study period. 
 
 
2.3.2.2. Spatial Analysis 
The distribution of Mortality of COPD patients who died during the study 
period by local area is visualized in figure 2.9. The local areas of Alexandre Bay (0.63), 
Trinity (0.62), Bay d’Espoir (0.60), Bonavista area (0.60), St. George’s area (0.59), and 
Labrador North (0.55) were found to have higher mortality. The results from spatial 
autocorrelation analysis of mortality among COPD patients revealed significant low 
clustering with a Moran’s I index of 0.047, and Z score of 2.52 (p-value=0.011). Local 
level analysis found the White Bay South area as a low-low cluster (p-value=0.05, 
LMI= 0.000014), and the Black Head Bay (p-value=0.006, LMI=0.000153) and 
Southern Bay areas (p-value=0.024, LMI=0.00018) as high-high clusters (figure 2.10). 
Mortality hotspots were found to be occurring in “somewhat accessible” and 
“accessible” A-R index classified areas. The predictors that led to the best-fitted models 
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at the community level were average age, and average number of specialist visits, 
average A-R index of place of residence (P=0.002). No OLS residual clustering was 
observed at the local level (figure 2.11), indicating no spatial dependencies while a 
global Moran’s I test uncovered a non-random distribution of residuals across the 
province (Moran’s I = 0.03, p-value=0.08).  
Table 2.8. Results of Global Moran’s I test on mortality among COPD patients 
Variable Mortality 
Moran’s Index 0.047 
Z-score 2.52 
p-value 0.011 
 
 
Figure 2.9. Distribution of mortality at local area level 1995-2014 
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Figure 2.10. Outlier and clusters of mortality at local area level 
 
 
Figure 2.11. Standard residuals of regression – Adjusted mortality at the community level 
Global Moran’s I =0.047 
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2.4. Discussion and Conclusion 
2.4.1. Main Findings of the Study 
Our study shows COPD patients from remote and less accessible areas are more 
prone to hospitalization and mortality. As the degree of remoteness of an area increases, 
so does the likelihood a COPD related hospitalization. A similar pattern was observed 
for mortality of COPD patients.  
The findings from our study are consistent with previous studies regarding the 
positive association between the degree of remoteness of an area and COPD 
hospitalization and mortality [6] [7]. Although there is no consistency in defining rural 
or remote in the literature [27]. To identify remoteness and rurality we used a definition 
standardized for NL[17]. Our analyses included multivariate modelling for individual 
and community level as well as spatial analysis.  
Analysis of the annual hospitalizations rates showed hot spots in more remote 
areas of the province while cold spots were more likely to occur in more accessible 
areas. One may say these cold spots and hot spots cannot be explained purely by A-R 
index classification; for example, the difference could be due to underlying systemic 
issues such as inequity in access to the healthcare services especially primary 
healthcare.  Using multivariate analysis controlling for healthcare utilization factors did 
not change the result of our study. In all of these models, COPD hospitalization and 
mortality were associated with the degree of remoteness even after controlling for the 
number of visits with primary care physicians and specialists. However, we did not 
have data allowing us to examine differences in the type of treatment options and 
availability of COPD related expenditures among these areas. 
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Although this study sheds light on the association between geographic 
accessibility and risk of hospitalization and mortality, the underlying reasons for this 
pattern is still unknown. Further studies are recommended to identify the role of 
smoking on these differences. Researchers could also look in more details for health 
status of the patients and the type of the services they receive. This information is vital 
in identifying the necessary steps that regional health authorities or individuals should 
take to reduce this risk.  
 
2.4.2. Limitations 
The result of this study should be interpreted in light of its limitations; This is a 
retrospective cohort study using secondary data. The secondary data in this study may 
have suffered data quality issues.  
Some risk factors of COPD hospitalization and mortality were not included in 
the dataset such as: socioeconomic status and type of medication prescribed to the 
patient. We were not able to control for smoking since there was no information in our 
datasets. Smoking is a well-known contributor to the increased risk of developing 
COPD and other life-threatening comorbidities and complications. 
We did not have information to differentiate planned and unplanned hospital 
admission nor were we able to identify the cause of hospital admission or cause of 
death. These factors may influence our results, as some of the hospital admissions or 
deaths may be unrelated to COPD.  
A-R index is not based on health authority’s level, and we do not have the 
information at this level, therefore we could not conduct the analysis at this level.  
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In our study, cases were identified using ICD-9 and ICD-10 codes, therefore our 
result relies heavily upon the accuracy of the COPD case definition algorithm. The data 
for this study came from hospital discharge and physician claims data. In NL, salary-
based physicians (approximately 30 percent of the total pool of active practicing 
physicians in the province) are not obligated or expected to submit medical fee claims, 
therefore the number of COPD patients might have been underestimated.   
 
2.4.3. Conclusion 
In order to solve complex population health problems, it is important to identify 
communities and regions that may require emergent attention. After controlling for 
physician visits, we found that COPD patients who live in inaccessible and remote areas 
are at a greater risk of hospitalization and mortality in Newfoundland and Labrador. 
Although limited by the data this study provides evidence for health planners in 
resource allocation and in designing targeted interventions to address the healthcare 
needs of COPD patients living in remote and rural regions of the province. 
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Chapter 3: Geographic Accessibility and Risk of Hospitalization and 
Mortality among Asthma Patients 
 
3.1. Introduction 
Asthma accounts for about 80% of chronic respiratory diseases in Canada, 
which makes it the most common respiratory chronic disease in this country [1]. Three 
million people in Canada and 235 million around the world are affected by asthma [2]. 
As stated by Statistics Canada, 8.1% of Canadians aged 12 and older have been 
diagnosed with asthma [3]. In Canada, 250 people die from Asthma annually and about 
70000 emergency visits are due to an asthma attack. Economic costs of asthma are one 
of the highest among chronic diseases as a consequence of health care utilization [4]. 
Asthma is considered as an ambulatory care-sensitive condition (ACSC) which means 
that hospital admissions are avoidable given proper primary health care services and 
early management. Previous research also shows that asthma hospitalization is highly 
preventable when the patients have access to quality healthcare [5]. However, asthma 
hospitalization is still high in most countries [6]. Concerned by this trend, it has been 
started to evaluate healthcare further, and identify potential contributors to the severe 
outcome of asthma patients. Severe outcome refers to hospitalization and mortality 
[4][7]. 
Evidence suggests that there are differences in hospitalization and mortality 
within and between regions. A few studies found higher rates in rural areas and a few 
others found higher rates in urban areas [8] [9] [10] [11]. These differences are 
justifiable since characteristics of rural areas vary in different parts of the world.  
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The spatial variation in asthma outcomes could be due to many factors. In 
previous studies, inaccessibility to health centers was mentioned as a risk factor for 
asthma hospitalization, and mortality [12]. Analysis of rural-urban differences in 
asthma hospitalization in Saskatchewan between 1970 and 1989 showed a higher rate 
(RR=1.5, CI:1.38-1.84) among rural residents in comparison to urban residents in 
patients 35 years old and younger. The results were not different for men or women. 
For children and young adults under 35, the difference was only significant before the 
year 1984. The authors discuss that one of the causes for higher admission rates in rural 
areas of Saskatchewan might be due to lower accessibility to health services. Rural 
residents live further from hospitals in comparison to urban residents [9].  In another 
study of children with asthma in an urban setting, they found higher accessibility to 
primary health care is significantly associated with higher scheduled visits, and lower 
unscheduled visits to an urban pediatric emergency department [13]. A. Jones, G. 
Bentham, and C. Horwell found that an increase in travel time to hospitals significantly 
increase mortality among asthma patients. The authors concluded that an improvement 
in access to acute care facilities would reduce the mortality rate among asthma patients 
[12]. Information on geographic accessibility to healthcare services is critical for the 
implementation of effective policies aiming to improve healthcare for asthma patients. 
 In our study, by assessing the association between the degree of remoteness, 
and hospitalization, and mortality of asthma patients among the adult population of 
Newfoundland and Labrador (NL) we will be able to identify the areas in NL at higher 
risk, which is critical for the development of effective healthcare policies. To our 
knowledge, this study is the first study that assesses the impacts of the place of 
residence on hospitalization and mortality among adults living with asthma in NL. We 
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hypothesize that asthma patients who live in more inaccessible areas will have a higher 
number of hospitalizations and mortality in comparison to patients that live in 
accessible areas.  
3.2. Methods 
3.2.1. Study Design 
We conducted a retrospective cohort using medico-administrative data from 
1995 to 2014. The patients were followed from diagnosis until the occurrence of study 
outcomes, the end of the study period (2014), or their death. 
3.2.2. Data Source 
The dataset for this study was retrieved from Newfoundland and Labrador 
health administrative data. For the purpose of this study, Newfoundland and Labrador 
Centre for Health Information (NLCHI), the data custodian, provided us with a de-
identified database. This database was developed via linkage with the following 
databases: the Canadian Chronic Disease Surveillance System (CCDSS), Clinical 
Database Management System (CDMS), Medical Care Plan (MCP) Fee-For-Service 
Physician Claims Database, and NLCHI Mortality System Database (MS). CCDSS is 
the network of the provinces’ and territories’ chronic disease surveillance [14]. CDMS 
includes demographic and clinical information of patients who received surgical day 
care or healthcare services by acute care facilities within the province [15]. MCP billing 
database includes information about the provided care under MCP by the fee-for-
service physicians [16]. MS database provides the death records within the province 
[17]. 
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The dataset provides information about the characteristics, hospitalization, 
comorbidities, and physician visits of patients who received medical care in the 
province between 1995 to 2014. The database includes approximately 600,000 records.  
3.2.3. Study Population 
The study population are adults living with asthma in NL. To meet the inclusion 
criteria, the patients must be 20 or older and must be diagnosed with asthma between 
the years of 1995, and 2014 in Newfoundland and Labrador. The cases are identified 
according to the CCDSS definition. To meet the criteria of this definition, the patient 
must have a record of diagnosis with asthma from a hospital admission (493 in ICD-9, 
J45 and J46 in ICD-10) or must have records of diagnosis with asthma in two physician 
visits within 730 days of the first visit (401-405 in ICD-9). A sensitivity of 83.6% (95% 
CI: 77.1–89.1) and specificity of 76.5% (95% CI: 71.8–80.8) have been reported for 
this case definition in Manitoba and Ontario [18]. 
3.2.4. Ethics and Consent 
The ethical approval’s references number is 20161500, which has been received 
from the Health Research Ethics Board in Newfoundland and Labrador.  
3.2.5. Geographic Accessibility 
The primary independent variable in this study was geographic accessibility.  In 
this study, patients are classified into two groups based on their place of residence at 
diagnosis. Accessibility of place of residence was evaluated based on the Accessibility 
Remoteness Index (A-R index), which was developed by the Newfoundland and 
Labrador Statistics Agency (NLSA). The areas within the province are classified based 
on their accessibility to governmental services such as primary and secondary health 
centers, pharmacies, dental clinics, high schools, and supermarkets. The index was 
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developed with a geographical approach, which refers to the fact that road distance 
restricts the interaction between the users and these services. Generally, the most 
accessible areas within the province are regional centers which have many public 
services. The lowest accessible areas within the province are remote areas where the 
residents only have access to regional centers via ferry or plane [19].  
 
 
Figure 3.12. Classification of the province of Newfoundland and Labrador based on A-R 
index [19] 
 
Figure 3.1 shows that the A-R index categorizes the province to the defined 
classes of highly accessible, accessible, somewhat accessible, moderately remote, and 
extremely remote areas [19].  
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3.2.6. Outcome 
Hospitalization is the primary outcome of our study. Hospitalization is a binary 
(yes or no) variable.  It is an incident case and it explains if the person has experienced 
any hospital admission, planned or unplanned during the observation period. 
Hospitalization was measured by person-year at risk.  
Annual hospitalization rate and mortality are secondary outcomes of this study. 
Annual hospitalization rate is calculated based on the number of hospital admissions 
per person-year at risk. Mortality is a dichotomous variable and describes if the person 
was alive during the study period. 
 
3.2.7. Covariates 
The covariates on the individual level are sex, age at the baseline. The variable 
age was categorized on the basis of 10-year age groups [20]. We also collected 
information on the number of comorbidities, and number of physician and specialist 
visits during the study period.   
Comorbidities include Hypertension, Chronic Obstructive Pulmonary Disease 
(COPD), Ischemic Heart Disease (IHD), Acute Myocardial Infarction (AMI), and Heart 
Failure. The comorbidities were identified based on the CCDSS method using ICD-9 
and ICD-10 codes [21]. For each patient, the number of comorbidities was calculated. 
We classified number of comorbidities as: zero, one, two, three and more.    
3.2.8. Analysis 
3.2.8.1. Individual Level Analysis 
We performed a descriptive analysis to describe the characteristics of the study 
population. Reporting the outcomes, we calculated person-year at risk for each patient. 
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In order to examine the differences between the inaccessible and accessible areas, 
bivariate analysis was performed. In the analysis, at the individual level, we used 
continuous A-R index, and at the local area level, we developed a fuzzy set model where 
we divided the areas to accessible and inaccessible [22]. 
The association between the place of residence and hospitalization of asthma 
patients was analyzed using logistic regression. The dependent variable is 
hospitalization, and the main independent variable is accessibility based on A-R index. 
The results were adjusted for sex, age, number of comorbidities, number of specialist 
visits and family physician visits, and interaction terms between A-R index and the 
other covariates. To find the optimum model a stepwise selection approach was used 
based on the smaller Akaike information criterion (AIC). We assessed the model’s 
fitness based on different combinations of family physicians, internists, pulmonologists 
and other specialists. The model including variables family physicians and all 
specialists was selected as it performed better than the other models according to AIC. 
Since the follow-up duration was different for each patient, a generalized linear model 
with “Complementary log-log function” was used, and log of person-year at risk 
(follow-up duration) was used as the offset term [23], [24], [25], [26]. A similar 
approach was used to develop a logistic regression model for assessing the relationship 
between the place of residence and mortality. 
To evaluate the association of place of residence and annual hospitalization rate, 
negative binomial regression was used due to the presence of overdispersion in the data 
(overdispersion test by Cameron and Trivedi) [27]. To control for the differences in the 
follow-up duration of each patient, log of follow up was used as an offset term. The 
model was adjusted for the number of comorbidities, gender, and age, family physician 
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and specialist visits. Interaction terms between A-R index and other covariates were 
added to the model. Similarly, we used a stepwise approach to find the model with the 
best fit. R studio Version 1.1.383 was used for performing the statistical analysis [28].  
3.2.8.2. Spatial Analysis 
The distribution of the study outcomes is visualized. The natural breaks was 
used for the visualization. In this study, local areas were identified according to the 
census consolidate subdivision (CCS). Local areas are intermediate geographic levels 
between census division and census subdivision [29]. We had access to maps and files 
through Memorial University which was provided by the government of Newfoundland 
and Labrador and NLSA. 
Using Global Moran’s I test, and Anselin Local Moran’s I (LMI) test, the 
existence of clusters were determined. In general, when the value of neighbouring 
features are similarly high or low, they all together make either high-high or low-low 
cluster. When the value of neighbors is either lower or higher, this makes high-low, or 
low-high outliers. If autocorrelation was observed, we developed an ordinary least 
square regression to identify the best model of asthma hospitalization, annual 
hospitalization rate, and mortality at the local area level.  
The model variables which had the best fit (p-value<0.1) was selected based on 
an iterative stepwise approach from the following variables: average A-R index, 
percentage of female with Asthma, average age at the time of diagnosis, percentage 
asthma patients with comorbidities, percentage of physician visits, and specialist visits 
during the follow up period at the local area level.  
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3.3. Result 
We identified 31613 asthma patients between 1995 and 2014. After removing 
the missing value for the place of residence (10.43%), we had 28316 records of patients 
living with asthma. The characteristics of the study population are presented in table 
3.1. Cumulative incidence of asthma by local area during the study period has been 
depicted in figure 3.2. It is visible that areas in eastern and southern Newfoundland 
have a higher cumulative incidence of asthma; for instance, in Bay L’argent Area, 
Terrenceville Area, Placentia Bay West, Placentia Bay North, Gambo Area the 
cumulative incidence of asthma was 0.59, 0.29, 0.26, 0.12 respectively. The overall 
person-year for the study population was 323795 person-years (mean = 11.44 person-
year, 95% CI: 11.37-11.55). On average the first event of hospital admission happened 
9.58 years (95% CI: 9.48-9.68) after the diagnosis of asthma. The average age of 
patients at the baseline was 47.69 years [95% CI: 47.48 - 48.89]. The most prevalent 
comorbidities were Hypertension (45%) followed by COPD (31%). As shown in Table 
3.2, asthma patients from less accessible areas face a higher number of hospital 
admissions per person-year in comparison to patients in accessible areas (0.20 versus 
0.19; p<0.001). Patients from areas with higher accessibility have a higher number of 
family physician visits per person-year (8.03 versus 7.35, p<0.001) and higher 
specialist visits (5.20 versus 4.42, p<0.001) per person-year. 
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Figure 13. 1. Cumulative incidence of asthma at the local area level in NL between 1995 and 2014 
 
Table 3.9. Characteristics of the study population according to the place of residence 
(N=28316) 
  Inaccessible (n=10595) Accessible 
 (n=17721) 
p-value a 
Sex (n, %)   <0.001 
Male 4172 (39.3%) 6457 (36.4%)  
Female 6423 (60.7%) 11264(63.6%)  
    
Age in years b    
Median (IQR) 49 (37, 63) 44 (32, 58) <0.001 
Mean (SD) 50.3 (18.3) 46.12 (19)  
20-29 1419 (13.4%) 3598 (20.3%) <0.001 
30-39 1754 (16.6%) 3772 (21.3%)  
40-49 2136 (20.2%) 3479 (19.6%)  
50-59 2027 (19.1%) 2696 (15.2%)  
60-69 1571 (14.8%) 1960 (11.1%)  
70-79 1115 (10.5%) 1440 (8.1%)  
>=80 573 (5.4%) 776 (4.4%)  
    
Comorbidities c   <0.001 
Zero  5494 (51.9%)  10946(61.8%)  
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Table 3.10. Healthcare utilization according to the place of residence (N=28316) 
 Inaccessible Accessible p-value 
Hospitalization incidence (PY) 0.11 0.09 <0.001 
    
Hospitalization rate (PY) 0.20 0.19 <0.001 
    
Mortality (PY) 0.02 0.01 <0.001 
    
    
Visit with Family Physicians (PY)     
Before the first hospitalization  2.02 2.46 0.3955 
Total visits  7.35 8.03 <0.001 
    
Visit with Pulmonologist/Internist 
(PY) 
   
Before the first hospitalization  2.3 2.8 0.1233 
Total visits  0.86 1.05 0.9422 
    
Visit with Other Specialists (PY)    
Before the first hospitalization 1.20 1.62 <0.001 
Total visits 4.42 5.20 <0.001 
    
 
One 2738 (25.8%)  3861 (21.8%)  
Two 1325 (12.5%) 1699 (9.6%)  
Three or more 1038 (9.8%) 1215 (4.9%)  
    
Comorbidities d     
Zero 3956 (37.3%) 8062 (45.5%) <0.001 
One 3003 (28.3%) 4828 (27.2%)  
Two 1997 (18.8%) 2725 (15.4%)  
Three or more 1639 (15.6%) 2106 (11.9%)  
    
Comorbidities e    
Zero 3161 (29.9%) 6818 (38.5%)                                
One 2798 (26.4%) 4570 (25.8%)  
Two 2070 (19.5%) 2998 (16.9%)  
Three or more 2566 (24.2%) 3335 (18.8%)  
    
Mortality (n, %) 2226 (21%) 2922 (16.5%) <0.001 
a Chi square test 
b Age at the time of diagnosis 
c Comorbidities at the time of diagnosis 
d Comorbidities before the first hospitalization 
e Comorbidities for the whole of the study period 
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3.3.1. Geographic Remoteness and Hospitalization 
3.3.1.1. Individual Level Analysis 
The results of logistic regression model (table 3.3) after adjusting for sex, age, 
number of comorbidities, indicated hospitalization is higher in remote and inaccessible 
areas. As the A-R index increases (decrease in accessibility), the likelihood of 
hospitalization among asthma patients increases significantly (OR=12.38, 95% 
CI:6.28-24.46, P<0.001).  
As shown in Table 3.4, annual hospitalization rate is higher in the areas with 
lower accessibility after adjustment for sex, age, the number of comorbidities, and the 
number of family medicine and specialist visits (RR=4.74, 95% CI:3.10-7.25, 
P<0.001). 
Table 3.11. Predictors of hospitalization among patients living with asthma in Newfoundland and 
Labrador 
Predictor OR 95% CI P-value 
AR INDEX a                 12.38 6.28-24.46 < 0.001 
Comorbidity b, c    
One             1.96 1.82-2.11 < 0.001 
Two             5.32 4.86-5.84 < 0.001 
Three or more           38.24 34.01-43.05 < 0.001 
Sex Female  2.55 2.33-2.79 < 0.001 
Age 30-39 d, e 0.69 0.61-0.78 <0.001 
Age 40-49  0.42 0.37-0.48 <0.001 
Age 50-59           0.62 0.53-0.71 <0.001 
Age 60-69 0.98 0.82-1.17 0.83 
Age 70-79           2.58 2.06-3.25 <0.001 
Age >=80 1.40 1.08-1.83 <0.001 
AR INDEX: Female        0.47 0.28-0.81 0.0063 
AR INDEX: Age 30-39 e 0.66 0.29-1.49 0.32 
AR INDEX: Age 40-49  1.69   0.75-3.80 0.21 
AR INDEX: Age 50-59  0.51   0.22-1.20 0.12 
AR INDEX: Age 60-69  0.52   0.19-1.39 0.19 
AR INDEX: Age 70-79  1.07   0.30-3.90 0.92 
AR INDEX: Age >=80 73.40   13.45-419-5 <0.001 
a Accessibility remoteness index 
b Number of Comorbidities at the time of diagnosis 
c Patients with no comorbidities are the reference group.  
d Age at the time of diagnosis 
e Age 20-29 class is the reference group.  
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Table 3.12. Predictors of annual hospitalization rate at the individual level among asthma 
patients 
Predictor RR 95% CI P  value 
AR INDEX a                 4.74 3.10-7.25 < 0.001 
Comorbidity b, c    
One             1.27 1.18-1.36 < 0.001 
Two             1.83 1.68-1.99 < 0.001 
Three or more           3.06 2.80-3.35 < 0.001 
Sex Female  1.13 1.08-1.19 <0.001 
Age 30-39 d, e 0.71 0.65-0.77 < 0.001 
Age 40-49  0.57 0.52-0.62 < 0.001 
Age 50-59           0.74 0.67-0.81 <0.001 
Age 60-69 1.14 1.03-1.27 0.010 
Age 70-79           1.84 1.65-2.06 < 0.001 
Age >=80 2.49 2.18-2.85 < 0.001 
Family Medicine visits f  0.9984 0.9982-0.9986 < 0.001 
Specialist visits g 1.009 1.008-1.009 < 0.001 
AR INDEX: Comorbidity=1 1.34 0.88-2.03 0.17 
AR INDEX: Comorbidity=2 0.78 0.49-1.25 0.31 
AR INDEX: Comorbidity>=3 0.80 0.49-1.31 0.37 
AR INDEX: Female 0.67 0.50-0.89 0.006 
AR INDEX: age 30-39 e       1.71 1.04-2.81 0.036 
AR INDEX: age 40-49        2.36 1.40-4.00 0.001 
AR INDEX: age 50-59       2.96 1.72-5.11 <0.001 
AR INDEX: age 60-69      3.06 1.69-5.55 <0.001 
AR INDEX: age 70-79      4.10 2.16-7.78 < 0.001 
AR INDEX: age >=80      4.22 1.98-8.98 < 0.001 
 
a Accessibility Remoteness index 
b Number of Comorbidities at the time of diagnosis 
c Patients with no comorbidities are the reference group.  
d Age at the time of diagnosis 
e Age 20-29 class is the reference group. 
f Number of family medicine visits for the whole study period 
g Number of specialist visits for the whole study period 
 
 
3.3.1.2. Spatial Level Analysis 
Cumulative incidence of hospitalization during the study period is depicted in 
figure 3.3. The highest cumulative hospitalization incidence are in Labrador east coast 
(1.00), Burgeo area (0.90), Pinware river (0.90), Roddicton area (0.89), Belle bay 
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(0.87), Buchans area (0.85), Strait of Belle Isle (0.84), St. George’s area (0.83), and 
Labrador north (0.83).  
The Global Moran’s I test of asthma Cumulative hospitalization incidence 
found statistically significant spatial autocorrelation at the alpha level of 0.05 (table 
3.5). According to the results (Global Moran’s I index=0.065 and Z score=3.29, 
P=0.001) there is less than 1% chance that this clustered pattern is due to randomness. 
Anselin Local Moran’s I (LMI) showed Labrador East coast (LMI=0.000136, 
P<0.002), Goose Bay (LMI=0.000024, P<0.002), Pinware River (LMI=0.000145, 
P<0.004), Roddickton Area (LMI=0.000131, P<0.026), Strait of Belle Isle 
(LMI=0.000144, P<0.004), Hawk’s Bay Port aux Choix (LMI=0.000068, P<0.012) as 
significant clusters of high value (high-high clusters). Grand Falls Point Leamington 
(LMI=0.000027, P<0.03), and St. Mary’s Bay (LMI=0.000062, P=0.02) as clusters of 
low value (low-low). As it is shown in figure 3.4, the cold spots (areas with lower 
Cumulative Hospitalization Incidence) are mostly in accessible regions; hot spots are 
in inaccessible regions.  
The results from goodness of fit from ordinary least square showed that the 
model fit the data well (Adjusted R2 = 0.9) and the significant variables were average 
A-R index, the average number of comorbidities, and percentage of female living with 
asthma in the community. We observed a significant association between average A-R 
index at the local level and cumulative hospitalization incidence (Coefficient=1.3, p-
value<0.001). The residuals of the model were visualized and presented in figure 3.5. 
The results of global Moran’s I test did not show any significant spatial autocorrelation, 
and the observed pattern is due to randomness (Moran’s Index = 0.02, p-value=0.12). 
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Table 3.13. Global Moran’s I summary on hospitalization and hospitalization rate among 
asthma patients 
Variable Cumulative incidence of hospitalizations 
Moran’s Index 0.065 
Z-score 3.29 
p-value 0.001 
 
Variable Annual hospitalization rate 
Moran’s Index 0.07 
Z-score 3.57 
p-value 0.0003 
 
 
Figure 3.14. Cumulative incidence of hospitalization at the local area level in NL between 1995 
and 2014 
      
57 
 
 
Figure 3.15. Outlier and clusters of cumulative incidence of hospitalization at the local area level 
 
Figure 3.16 Standard residuals of ordinary least square regression- Adjusted hospitalization 
incidence at the local area level 
       
Global Moran’s I =0.065 
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Distribution of annual hospitalization rate is visualized and presented in figure 
3.6. Harbour Breton area (1.2), Burgeo area (1.0), Belle Bay (0.9), Labrador north (0.9), 
Buchans area (0.8), Labrador east coast (0.8) are among the regions with the highest 
annual hospitalization rate. All of these regions are located in inaccessible areas. The 
Global Moran’s I test found significant autocorrelation (alpha=0.05) of annual 
hospitalization rate (Global Moran’s I index 0.07, and Z score=3.57, P=0.0003)). 
According to this index, there is less than 1% chance that this clustered pattern is due 
to randomness. Anselin Local Moran’s I found Hermitage Bay as high-high cluster (P= 
0.022, LMI=0.000101). Local Moran’s I test also identified low-low clusters 
statistically significant in eastern and southeastern of NL, as it was shown in figure 3.7.  
At the local level, the ordinary least square regression model with average A-R 
index, average age, and the average number of physician and specialist visits during the 
study period had the best fit (Adjusted R2 = 0.59). This model shows an increase in 
average A-R index at the local area level is associated with an increase in average 
annual hospitalization rate (P<0.001). The visualization of the residuals is presented in 
figure 3.8, the global Moran’s I test of residuals indicated no spatial autocorrelation of 
residuals (Moran’s I= -0.000005, p-value=0.59) and the observed pattern is not 
significantly different from random. 
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Figure 3.17 Distribution of annual hospitalization rate at the local area level 
         
 
 
Figure 3.18 Outlier and clusters of the annual hospitalization rate at the local area 
Global Moran’s I =0.07 
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Figure 3.19 Standard residuals of ordinary least square regression – Adjusted annual 
hospitalization rate at the local area level 
          
 
 
3.3.2. Geographic Remoteness and Mortality 
3.3.2.1. Individual Level Analysis 
The result of the adjusted logistic regression model is presented in table 3.6.  
Using this model, we controlled for comorbidity, sex, age, number of family medicine 
and specialist visits during the study period. Overall the results did not show any 
significant association between A-R index and mortality among asthma patients 
(OR=3.55, 95% CI; 0.30-32.9, P=0.29).  
Table 3.14.  Predictors of Mortality at the individual level 
Predictor OR 95% CI P > z 
AR INDEX a                 3.55 0.30-32.9 0.29 
Comorbidity b, c    
One             1.51 1.17-1.94 0.001 
Two             2.43 1.89-3.14 < 0.001 
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Three or more           7.63 5.94-9.84 < 0.001 
Sex Female  0.67 0.59-0.76 <0.001 
Age 30-39 d, e 1.67 1.05-2.68 0.03 
Age 40-49 4.02 2.64-6.26 < 0.001 
Age 50-59           8.71 5.76-1.35 < 0.001 
Age 60-69 2.78 1.83-4.29 < 0.001 
Age 70-79           9.43 6.19-1.47 < 0.001 
Age >=80 5.15 3.26-8.32 < 0.001 
Family Medicine visits f 0.994 0.993-0.995 < 0.001 
Specialist visits g 1.002 1.001-1.003 < 0.001 
AR INDEX: Comorbidity=1 0.85 0.21-3.39 0.81 
AR INDEX: Comorbidity=2 0.32 0.079-1.35 0.12 
AR INDEX: 
Comorbidity>=3 
0.23 0.059-0.89 0.03 
AR INDEX: Female 0.50 0.24-1.03 0.06 
AR INDEX: Age 30-39 1.39 0.009-24.4 0.82 
AR INDEX: Age 40-49 1.10 0.024-1.03 0.94 
AR INDEX: Age 50-59 0.61 0.05-8079 0.71 
AR INDEX: Age 60-69 0.54 0.53-0.04 0.63 
AR INDEX: Age 70-79 1.42 0.11-21.00 0.79 
AR INDEX: Age >=80 0.64 0.04-11.3 0.76 
a Accessibility Remoteness index 
b Number of Comorbidities at the time of diagnosis 
c Patients with no comorbidities are the reference group.  
d Age at the time of diagnosis 
e Age 20-29 class is the reference group. 
f Number of family medicine visits for the whole study period 
g Number of specialist visits for the whole study period 
 
3.3.2.2. Spatial Level Analysis 
The distribution of mortality among patients living with asthma at the local area 
level is visualized and presented in figure 3.9. Labrador east coast (1.00) Burgeo area 
(0.45), and St. George’s area (0.45) has the highest mortality among asthma patients, 
respectively. The Global Moran’s I index is 0.006973, and the Z score is 0.98 with the 
p-value of 0.33 (table 3.7). The results showed no geographic autocorrelation.  
Table 3.15. Global Moran’s I summary on mortality among asthma patients 
Variable Mortality 
Moran’s Index 0.006973 
Z-score 0.98 
p-value 0.33 
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Figure 3. 20. Distribution of mortality at the local area level 1995-2014 
       
 
 
3.4. Discussion and Conclusion 
3.4.1. Main Findings of the Study 
Using population-based data from two decades in NL, we conducted both 
individual and local area level analyses, we found geographical differences in 
hospitalization and annual hospitalization rate. No association was observed between 
the place of residence and mortality of asthma patients.   
The findings of this study are in line with some studies in North America [12] 
[30] [31]. One study in Saskatchewan showed hospitalization rate of asthma patients 
was higher in rural areas [12]. Another study in Washington, found accessibility to 
health centres as a contributing factor to lower emergency visits of asthmatic children 
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[30]. In New South Wales, Australia, hospitalization rate was 51.2-69.1% and mortality 
rate was 3.62-42.85% higher in the rural areas versus urban areas [31].  
We did not find any significant association between place of residence and 
mortality; however, studies in other provinces of Canada show inaccessibility is 
associated with higher mortality among asthma patient [12]. The finding of these 
studies could be affected by the geographic classification of the areas. In our study we 
used a classification standardized for NL, where we focus on an inaccessible-accessible 
continuum based on access to goods and services [19]. This index is not representative 
of the spectrum of geography in other regions. This also may account for the differences 
between studies 
One may say, the observed spatial pattern in hospitalization could be due to 
many factors including the differences in the healthcare utilization. In our study, using 
both individual level and local area level analyses, hospitalization was associated with 
the degree of remoteness even after controlling for the number of visits with physicians 
and specialists. 
Although the cumulative incidence of asthma was higher in more accessible 
areas, the hospitalization incidence was higher in less accessible areas of NL. The 
observed difference might be due to many factors including the differences in the 
availability and delivery of healthcare in these areas. Further study is recommended to 
identify the underlying causes of this difference. 
Although our study shows asthma patients who live in remote and less 
accessible areas are at higher risk of hospitalization, many important research questions 
regarding underlying causes remained unanswered. Future studies can address the 
effects of smoking on the pattern we identified on this study. They could also 
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investigate the health status of the patients and the type of care they received 
thoroughly. 
3.4.2. Limitations 
Several limitations might have impacted the results. This study uses secondary 
dataset, where the quality of data is always under question. We did not have information 
on the cause of hospital admissions or deaths, nor could we distinguish between 
unplanned and planned hospitalization. We did not have information on some risk 
factors which might affect hospitalization and mortality, including smoking and socio-
economic factors. A-R index is not based on health-authority’s level; therefore, we were 
not able to perform the analysis at this level. We used medico-administrative data and 
identified asthma cases using ICD-9 and ICD-10 codes. The results of this study are 
influenced by the accuracy of case definition algorithms.  This is a longitudinal study 
between 1995 and 2014, we did not account for the evolution of healthcare during this 
time. To account for this factor, a time series analysis is recommended. 
3.4.3. Conclusion 
One out of four patients with asthma lives in inaccessible areas in NL. These 
patients are older and suffer from a higher number of comorbidities. Living in 
inaccessible areas is associated with higher risk of hospitalization.  Identifying 
communities and regions at higher risk of hospitalization is essential for evidence-
informed decision making and to help in resource allocation and disease management. 
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Chapter 4.  Summary 
COPD and asthma are two of most important respiratory chronic diseases. 328 
million people deals with COPD in the world [1], and asthma affects about 300 million 
in the world [2]. COPD and asthma are great burdens for the world. COPD and asthma 
hospital admissions usually happen following exacerbation. COPD is expected to be 
the third leading cause of death in the world by 2030 [3]. This thesis focused on the 
assessment of spatial disparity of chronic respiratory diseases in Newfoundland and 
Labrador (NL). 
Literature shows that differences exist in spatial distribution of hospitalization 
and mortality of COPD and asthma in various regions of the world. Previous studies 
mainly focused on rural-urban differences of COPD and asthma. Whereas, our study 
took a closer look at this disparity by making use of accessibility remoteness index. 
Understanding geographic differences is required for effective management of the 
chronic respiratory diseases. Our study focused on Newfoundland and Labrador. To the 
best of our knowledge this is the first study that assess the association of place of 
residence and respiratory chronic diseases (i.e. COPD and asthma) outcome in NL. We 
aimed to determine if asthma and COPD patients who live in the areas with lower 
accessibility experience higher hospitalization and mortality. We designed a 
retrospective cohort using medico-administrative data. We conducted our analyses at 
individual and local area levels. At the individual level we made use of logistic and 
negative binomial regressions to find the association between accessibility of place of 
residence and COPD, asthma outcomes. At the local area level, we applied Global and 
Local Moran’s I to find spatial autocorrelation, and we performed ordinary least square 
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regression to analyze the effect of accessibility of place of residence on COPD, and 
asthma outcomes at the local area level.  
Overall 73 192 patients diagnosed with COPD and asthma are identified. 44 876 
COPD patients, and 28 316 asthma patients were included. Approximately 43.8% of 
COPD patients and 37.4% asthma patients live in inaccessible areas. 9 655 patients are 
diagnosed with both COPD and asthma, 41% of them living in inaccessible areas. The 
mean age at the time of diagnosis of COPD patients and asthma patients were 
respectively 63.03 (±14.42), and 47.69 (±17.59).  
Our results showed that after adjustment for age, sex, number of comorbidities, 
number of physician visits and number of specialist visits, living in places with lower 
accessibility areas significantly increase hospitalization incidence and annual 
hospitalization rate for both COPD and asthma patients. Higher likelihood of 
hospitalization was observed in both COPD (OR=2.57, 95% CI 1.54-4.25, P 
value=0.00136) and asthma patients (OR=12.38, 95% CI:6.28-24.46, P<0.001) who 
live in remote and inaccessible areas. COPD (RR=5.05, 95% CI:3.00-8.51, P 
value<0.001) and asthma patients (RR=4.74, 95% CI:3.10-7.25, P<0.001) from the 
areas with lower accessibility experience higher annual hospitalization rate. 
Nearly 41.1% of COPD patients, and 18.2% of asthma patients died during the 
study period. Mortality among COPD patients and asthma patients were 5.1, and 1.6 
per 100 person-year respectively. The results of our study showed COPD patients from 
remote and inaccessible areas were more likely to pass away (OR=10.73, 95% CI; 2.27-
44.77, P=0.002). We did not find any association between mortality of asthma patients, 
and accessibility of place of residence (OR=3.55, 95% CI; 0.30-32.9, P=0.29). 
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At the local area level, we found COPD hospitalization (Moran-Index=0.034, 
p<0.03), COPD annual hospitalization rate and COPD mortality (Moran-Index I=0.047, 
p<0.011) to be spatially autocorrelated. We found spatial autocorrelation for the 
hospitalization (Moran-Index=0.065,p<0.001), and annual hospitalization rate of 
asthma patients (Moran-Index=0.07,p<0.001), but not mortality (Moran-
Index=0.006973, p=0.33). 
Using the ordinary least square regression at the local area level, we observed a 
significant association between accessibility of place of residence and cumulative 
hospitalization incidence (P<0.001), annual hospitalization rate (p<0.05), and mortality 
(p=0.002) of COPD patients. The association was also observed in cumulative 
hospitalization incidence (P<0.001), and annual hospitalization rate (P<0.001) of 
asthma patients.  
Our results are in line with previous studies on hospitalization and mortality of 
chronic respiratory disease patients in relation to geography. For example, one study in 
Australia identified higher hospitalization of COPD patients in rural areas in 
comparison with the urban areas. A significant association was also observed between 
the degree of remoteness and hospitalization [4]. In the United States, COPD patients 
from rural and isolated areas were at higher risk of exacerbation and mortality [5]. 
Asthma patients in rural areas of Saskatchewan had higher hospitalization rates [6]. No 
association of accessibility of place of residence and mortality of asthma patients was 
observed in our study. However, in Australia, they found that asthma patients who have 
lower accessibility to the health centres experience higher mortality rates [7].   
One out of three asthma patients and two out of five COPD patients in 
Newfoundland and Labrador live in rural areas. The results of our study indicate that 
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asthma and COPD patients living in inaccessible areas are at higher risk of 
hospitalization and mortality. Identifying the regions at higher risk is necessary in order 
to enhance healthcare services and disease management for patients. Further studies are 
recommended to discover the underlying factors of these differences.  
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Appendix 
Table A1- Cumulative Hospitalization Incidence of COPD Patients 
Local areas         Cumulative Hospitalization Incidence 
Isthmus of Avalon 0.72 
Placentia-St. Bride's Area 0.81 
Heart's Delight Area 0.70 
New Perlican-Winterton Area 0.77 
North Shore of Conception Bay 0.78 
Carbonear Area 0.70 
Harbour Grace Area 0.74 
Spaniard's Bay Area 0.69 
Bay Roberts Area 0.62 
Clarke's Beach Area 0.68 
Head of Conception Bay 0.72 
Bell Island 0.76 
Southern Shore 0.70 
Trepassey Bay 0.72 
St. Mary's Bay 0.74 
Whitbourne Area 0.69 
Northeast Avalon 0.68 
Placentia Bay West Centre 0.72 
St. Lawrence Area 0.80 
Lamaline Area 0.73 
Fortune-Grand Bank Area 0.84 
Bay L'Argent Area 0.73 
Terrenceville Area 0.90 
Placentia Bay North West 0.78 
Belle Bay 0.91 
Harbour Breton Area 0.92 
Hermitage Bay 0.84 
Burgeo Area 0.69 
Port aux Basques Area 0.75 
Rose Blanche Area 0.77 
Codroy Valley 0.73 
Crabbes River 0.82 
St. George's Area 0.85 
Stephenville-Port au Port Peninsula 0.80 
Deer Lake-Cormack Area 0.76 
Corner Brook-Pasadena Area 0.72 
Bay of Islands 0.71 
Jackson's Arm Area 0.83 
Grand Falls-Point Leamington Area 0.72 
Gander Area 0.73 
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Wesleyville Area 0.77 
Greenspond Area 0.76 
Alexander Bay 0.86 
Chandlers Reach 0.76 
Southern Bay Area 0.77 
Catalina Area 0.78 
Trinity, Trinity Bay Area 0.79 
Smith Sound-Random Island 0.78 
South West Arm Area 0.85 
Gambo Area 0.84 
White Bay South 0.75 
Halls Bay 0.72 
Pilley's Island Area 0.61 
New World Island 0.80 
Twillingate Island 0.89 
Hamilton Sound 0.75 
Straight Shore 0.80 
Fogo and Change Islands 0.79 
Burlington Area 0.75 
King's Point Area 0.65 
Bonne Bay Area 0.79 
Strait of Belle Isle 0.86 
Quirpon-Cook's Harbour Area 0.89 
Norris Arm Area 0.70 
Roddickton Area 0.90 
Hawke's Bay-Port au Choix Area 0.73 
Daniel's Harbour Area 0.77 
Pinware River 0.96 
Goose Bay Area 0.87 
Labrador West 0.67 
Labrador North 0.98 
Buchans Area 0.81 
Bay d'Espoir Area 0.80 
Lewisporte Area 0.52 
Notre Dame Bay South 0.61 
Burin Area 0.74 
Mortier Bay 0.75 
Black Head Bay 0.83 
Bonavista Area 0.86 
Labrador East Coast ------a 
 
a The areas with patients less than 5 are filtered. 
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Table A1- Cumulative Hospitalization Incidence of COPD Patients 
Local areas         Cumulative Hospitalization Incidence 
Isthmus of Avalon 64.36 
Placentia-St. Bride's Area 70.19 
Heart's Delight Area 66.10 
New Perlican-Winterton Area 65.87 
North Shore of Conception Bay 68.12 
Carbonear Area 67.29 
Harbour Grace Area 68.24 
Spaniard's Bay Area 68.99 
Bay Roberts Area 64.16 
Clarke's Beach Area 63.41 
Head of Conception Bay 65.94 
Bell Island 67.19 
Southern Shore 59.91 
Trepassey Bay 76.32 
St. Mary's Bay 62.10 
Whitbourne Area 59.82 
Northeast Avalon 55.66 
Placentia Bay West Centre 55.07 
St. Lawrence Area ------------- a 
Lamaline Area 79.37 
Fortune-Grand Bank Area 72.08 
Bay L'Argent Area 55.98 
Terrenceville Area 51.37 
Placentia Bay North West 53.16 
Belle Bay 86.79 
Harbour Breton Area 71.74 
Hermitage Bay 75 
Burgeo Area 90.91 
Port aux Basques Area 66.91 
Rose Blanche Area 50 
Codroy Valley 64.56 
Crabbes River 76.47 
St. George's Area 82.35 
Stephenville-Port au Port Peninsula 70.37 
Deer Lake-Cormack Area 62.03 
Corner Brook-Pasadena Area 59.75 
Bay of Islands 65.90 
Jackson's Arm Area 55 
Grand Falls-Point Leamington Area 62.89 
Gander Area 57.61 
Wesleyville Area 66.90 
Greenspond Area 69.41 
Alexander Bay 57.92 
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Chandlers Reach 65.28 
Southern Bay Area 60.26 
Catalina Area 65.62 
Trinity, Trinity Bay Area 61.29 
Smith Sound-Random Island 60 
South West Arm Area 70 
Gambo Area 52.38 
White Bay South 64.29 
Halls Bay 65.32 
Pilley's Island Area 62.16 
New World Island 70.67 
Twillingate Island 72.73 
Hamilton Sound 57.31 
Straight Shore 65.59 
Fogo and Change Islands 64.62 
Burlington Area 62.86 
King's Point Area 58.34 
Bonne Bay Area 74.29 
Strait of Belle Isle 83.88 
Quirpon-Cook's Harbour Area 75.90 
Norris Arm Area 69.05 
Roddickton Area 88.89 
Hawke's Bay-Port au Choix Area 75.38 
Daniel's Harbour Area 72.55 
Pinware River 90.62 
Labrador East Coast ------------- a 
Goose Bay Area 77.95 
Labrador West 56.40 
Labrador North 82.35 
Buchans Area 85.42 
Bay d'Espoir Area 73.34 
Lewisporte Area 56.92 
Notre Dame Bay South 59.70 
Burin Area 65.80 
Mortier Bay 52.63 
Black Head Bay 73.08 
Bonavista Area 67.54 
a The areas with patients less than 5 are filtered. 
 
 
 
